Literature DB >> 2526111

Comparative in-vitro activity of vancomycin, teicoplanin, ramoplanin (formerly A16686), paldimycin, DuP 721 and DuP 105 against methicillin and gentamicin resistant Staphylococcus aureus.

P A Maple1, J M Hamilton-Miller, W Brumfitt.   

Abstract

The in-vitro activities of five anti-staphylococcal agents, teicoplanin, ramoplanin, paldimycin, DuP 721 and DuP 105 have been compared to vancomycin. Minimum inhibitory concentrations (MICs) and minimum bactericidal concentrations (MBCs) have been determined for a collection of methicillin and gentamicin resistant Staphylococcus aureus (MGRSA), comprising 75 strains obtained from 22 centres. In terms of geometric mean MICs (inoculum size 10(5) cfu) paldimycin was the most active agent (0.4 mg/l) followed by ramoplanin (0.75 mg/l), teicoplanin (1.0 mg/l), DuP 721 and vancomycin (2.0 mg/l) and DuP 105 (6.8 mg/l). Ramoplanin was bactericidal within six hours to all strains at a concentration of 1.0 mg/l. The MBC90s for vancomycin and teicoplanin were greater than 32 mg/l after 22 h exposure to antibiotic and 2.5 and 4.0 mg/l respectively after 26 h exposure. Paldimycin was bactericidal against only some strains, while DuP 721 and DuP 105 were not bactericidal. Ramoplanin is the most interesting of the new antibiotics, on account of its rapid and consistent bactericidal activity.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2526111     DOI: 10.1093/jac/23.4.517

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  14 in total

Review 1.  Teicoplanin. A pharmacoeconomic evaluation of its use in the treatment of gram-positive infections.

Authors:  C M Spencer; H M Bryson
Journal:  Pharmacoeconomics       Date:  1995-04       Impact factor: 4.981

2.  Complexation of peptidoglycan intermediates by the lipoglycodepsipeptide antibiotic ramoplanin: minimal structural requirements for intermolecular complexation and fibril formation.

Authors:  Predrag Cudic; James K Kranz; Douglas C Behenna; Ryan G Kruger; Hellina Tadesse; A Joshua Wand; Yuri I Veklich; John W Weisel; Dewey G McCafferty
Journal:  Proc Natl Acad Sci U S A       Date:  2002-05-28       Impact factor: 11.205

Review 3.  Cyclic lipodepsipeptides: a new class of antibacterial agents in the battle against resistant bacteria.

Authors:  Nina Bionda; Jean-Philippe Pitteloud; Predrag Cudic
Journal:  Future Med Chem       Date:  2013-07       Impact factor: 3.808

4.  Gastrointestinal tract colonization with vancomycin-resistant Enterococcus faecium in an animal model.

Authors:  M S Whitman; P G Pitsakis; E DeJesus; A J Osborne; M E Levison; C C Johnson
Journal:  Antimicrob Agents Chemother       Date:  1996-06       Impact factor: 5.191

5.  In vitro activities of ramoplanin, selected glycopeptides, fluoroquinolones, and other antibiotics against clinical bloodstream isolates of gram-positive cocci.

Authors:  T Lawrence; C Rotstein; T R Beam; E A Gorzynski; D Amsterdam
Journal:  Antimicrob Agents Chemother       Date:  1993-04       Impact factor: 5.191

6.  A critical review of oxazolidinones: an alternative or replacement for glycopeptides and streptogramins?

Authors:  G G Zhanel; C Shroeder; L Vercaigne; A S Gin; J Embil; D J Hoban
Journal:  Can J Infect Dis       Date:  2001-11

7.  Comparative in vitro activities of teicoplanin, daptomycin, ramoplanin, vancomycin, and PD127,391 against blood isolates of gram-positive cocci.

Authors:  D Shonekan; D Mildvan; S Handwerger
Journal:  Antimicrob Agents Chemother       Date:  1992-07       Impact factor: 5.191

8.  Ramoplanin susceptibility testing criteria.

Authors:  A L Barry; M A Pfaller; P C Fuchs
Journal:  J Clin Microbiol       Date:  1993-07       Impact factor: 5.948

9.  Differing activities of quinolones against ciprofloxacin-susceptible and ciprofloxacin-resistant, methicillin-resistant Staphylococcus aureus.

Authors:  P A Maple; J M Hamilton-Miller; W Brumfitt
Journal:  Antimicrob Agents Chemother       Date:  1991-02       Impact factor: 5.191

10.  Bactericidal activity of ramoplanin against antibiotic-resistant enterococci.

Authors:  C C Johnson; S Taylor; P Pitsakis; P May; M E Levison
Journal:  Antimicrob Agents Chemother       Date:  1992-10       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.